Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:EU EMA/INS/GCP/856758/ 2018 Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic) 06-Dec-2018 3.5.2: Difference between revisions

From GxPlex

Jump to: navigation, search
m 1 revision imported
gxplex>GxPlexBot
Import from GxPlex Excel
Line 11: Line 11:
{{:Document:EU EMA/INS/GCP/856758/ 2018 Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic) 06-Dec-2018}}
{{:Document:EU EMA/INS/GCP/856758/ 2018 Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic) 06-Dec-2018}}


{| class="gplx-infobox"
{| class="wikitable gplx-infobox"
|-
|-
! colspan="2" class="gplx-infobox-header" | Reference Details
! colspan="2" class="gplx-infobox-header" | Reference Details

Revision as of 15:27, 29 June 2026



Document information
Reference EU EMA/INS/GCP/856758/ 2018

Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic) 06-Dec-2018

Validity area EU
Scope(s) G
Document name EMA/INS/GCP/856758/ 2018

Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic)

Version / Revision 06-Dec-2018
Status Current
Document type Official guideline
Language(s) EN
Description EMA/INS/GCP/856758/2018

Good Clinical Practice Inspectors Working Group (GCP IWG)

Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic)

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Scope G
Document part 3.5.2
Language EN
Original entry by Florian Adragna
Contributors
Tags (EN)
Tags (original language)
Tags (FR)
Comment Handling superseded documents during trial

Content

3.5.2. Superseded documents During a document’s development (e.g. clinical trial protocol development and release), the sponsor’s/CRO’s procedures may require input and review by various functions. The documentation to demonstrate that the process was followed should be retained. Superseded versions of final documents are necessary to reconstruct the trial and should therefore be retained in the TMF. Superseded versions of sponsor-produced documents (e.g. trial protocol, IB and eCRF) should be present in the investigator/institution TMF in a manner to enable reconstruction without the need to access the sponsor TMF, with evidence of date of receipt, review and/or approval (when necessary) and date of implementation by the investigator/institution.